|
Home
|
|
Symptoms
|
|
Live Discussion
|
|
Diagnosis
|
|
Treatment
|
|
World-wide Support Finder
|
|
Library
|
|
Research
|
|
Lymelinks
|
|
Contact
|
|
Pets & Lyme
|
|
DONATIONS
|
|
Drug Info
|
|
Medical Dictionary
|
|
Board of Directors
|
|
|
No Warranties or Representations
Lyme Disease symptoms vary from person to person. (lymes disease lyme's disease lime disease limes disease)
The data and information presented in this web site are presented in good faith and believed to be accurate regarding Lyme disease (commonly misspelled lymes disease lyme's disease lime disease limes disease) and other related diseases. Any and all liability for the content or any omissions including any inaccuracies, errors, or misstatements in such data or information is expressly disclaimed. The web site is compiled for the sole purpose of informing community members of resources and information pertaining to Lyme Borreliosis Disease and its coinfections. Lyme disease symptoms may vary from person to person.
The Canadian Lyme Disease Foundation, Directors and members are not liable for any direct or indirect damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action arising out of or in connection with the use or performance of information available from this website.
Consult a qualified Lyme ( Borreliosis ) Disease literate doctor for medical advice if Lyme Disease is suspect to discuss your Lyme Disease Symptoms.
|
International Journal for Clinical and Investigative
Dermatology
Vol. 211, No. 2, 2005
Medline Abstract (ID 16088158)
Pharmacology and Treatment
Gabapentin for the Symptomatic Treatment of Chronic
Neuropathic Pain in Patients with Late-Stage Lyme
Borreliosis: A Pilot Study
S. Weissenbacher, J. Ring, H. Hofmann
Department of Dermatology and Allergy Biederstein,
Technical University of Munich, Munich, Germany
Dermatology 2005;211:123-127 (DOI: 10.1159/000086441)
Abstract
Background: Chronic neuropathic pain occurs in 10-15% of
patients with neuroborreliosis and is difficult to treat.
Objective: We evaluated the effect of gabapentin
monotherapy on residual pain in patients with
neuroborreliosis after intravenous ceftriaxone treatment.
Methods: Ten patients with neuroborreliosis and a
long-lasting history of neurologic symptoms were treated
with gabapentin, starting with 300 mg/day. Doses were
raised over a period of 4-12 weeks to the individually
effective and tolerated maximum dose (500-1,200 mg).
Treatment was maintained until pain disappeared and then
gradually reduced in dose over weeks. If symptoms recurred,
the doses were raised again. Therapy was maintained over an
average of 1-2 years.
Results: Pain quality and pain quantity were evaluated
using the McGill pain questionnaire and a visual analogue
scale. There was an improvement of 'crawling' and 'burning'
pain sensations, neck and radiating lumbar pain in 9/10
(90%) patients as well as a positive effect on mood,
general feeling of health and quality of sleep in 5/10
(50%) patients. The average dose leading to a clear-cut
pain reduction was 700 mg.
Conclusions: In an open pilot study (10 patients),
gabapentin monotherapy which has to our knowledge not been
published as treatment of chronic neuropathic pain in
patients with late Lyme borreliosis is efficacious in
treating pain associated with neuroborreliosis and can thus
improve quality of life in these patients.
Author Contacts
Prof. Dr. H. Hofmann
Department of Dermatology and Allergy Biederstein
Biedersteinerstrasse
29
DE-80802 München (Germany)
Tel. +49 89 4140 3181, Fax +49 89 4140 3581,
E-Mail
H.Hofmann@lrz.tum.de
Article Information
Received: August 6, 2004
Accepted: October 8, 2004
Number of Print Pages : 5
Number of Figures : 1, Number of Tables : 1, Number of
References : 30
|
| | |
